PMN ProMIS Neurosciences Inc.
$13.56▲ +1.19%
Healthcare
Other
After hours
$13.56▲ +0.00%
Sep 11, 7:30 PM ET
Volume 20.0K
Avg Volume (10D) 50.8K
Key Metrics & Fundamentals
Market Cap
$121.60M
P/E Ratio
–
Div Yield
–%
52W Range
6.27 - 27.40
% vs 50 MA
-2.88%
% vs 200 MA
8.38%
RSI-14
48.6
MACD Histogram
-0.1000
Beta (1Y vs SPY)
1.11
Free Cash Flow
-$10.39M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$12.27M
COGS
–
Operating Exp
$12.27M
Operating Income
-$12.27M
EBIT
-$12.27M
Pretax Income
-$11.73M
Net Income
-$11.73M
EPS (Diluted)
-1.28
Price & Volume History
Loading chart…
Recent News
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
GlobeNewswire · Sep 1, 2026 12:00 PM
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ...
GuruFocus.com · Aug 14, 2026 5:02 AM
Promis Neurosciences Q2 Earnings Call Highlights
MarketBeat · Aug 14, 2026 2:04 AM
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
GlobeNewswire · Aug 13, 2026 8:00 PM
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
GlobeNewswire · Aug 3, 2026 8:00 PM
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data
MarketBeat · Jul 28, 2026 6:04 PM
Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating
MT Newswires · Jul 28, 2026 2:46 PM
ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results
InvestorsHub · Jul 28, 2026 12:25 PM
ProMIS Neurosciences Says PMN310 Alzheimer Drug Shows Positive Interim Safety, Biomarker Data
MT Newswires · Jul 28, 2026 12:19 PM
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
GlobeNewswire · Jul 28, 2026 10:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See PMN's money flow as a full page
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.